Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

VYNE Therapeutics (VYNE) Revenue (2016 - 2025)

Historic Revenue for Therapeutics (VYNE) over the last 10 years, with Q3 2025 value amounting to $169000.0.

  • Therapeutics' Revenue rose 3966.94% to $169000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $555000.0, marking a year-over-year increase of 1167.0%. This contributed to the annual value of $501000.0 for FY2024, which is 1816.04% up from last year.
  • Latest data reveals that Therapeutics reported Revenue of $169000.0 as of Q3 2025, which was up 3966.94% from $100000.0 recorded in Q2 2025.
  • In the past 5 years, Therapeutics' Revenue registered a high of $295000.0 during Q2 2021, and its lowest value of $29000.0 during Q4 2022.
  • Moreover, its 5-year median value for Revenue was $133000.0 (2021), whereas its average is $149052.6.
  • Per our database at Business Quant, Therapeutics' Revenue crashed by 9747.6% in 2021 and then soared by 16206.9% in 2023.
  • Quarter analysis of 5 years shows Therapeutics' Revenue stood at $273000.0 in 2021, then crashed by 89.38% to $29000.0 in 2022, then surged by 162.07% to $76000.0 in 2023, then rose by 10.53% to $84000.0 in 2024, then surged by 101.19% to $169000.0 in 2025.
  • Its last three reported values are $169000.0 in Q3 2025, $100000.0 for Q2 2025, and $202000.0 during Q1 2025.